Kornimate/medical-research-clean huggingface dataset:
wound additives in primary total joint athroplasty

Conditions: Arthroplasty, Replacement

Summary: 3 cohorts of total joint patient of 30 members each were randomized to receive prp or activated collegen or no additive were studied for status of the wound at 6 weeks and recorded all complications, infections and reoperations. the three groups were than compared for statistical analysis

background: wound healing remains a concern in primary total joint arthroplasty given the risk of deep infections arising from hematomas, wound separations, and superficial infections. if wound additives can prevent these early complications, their universal application would be cost effective. this study examined whether two wound additives, platelet-rich plasma (prp) and celleraterx® (activated collagen), would improve postoperative wound healing and reduce complications in primary total joint arthroplasty. methods: a prospective, randomized, controlled study using three cohorts with 30 patients each (group 1: prp, group 2: activated collagen, group 3: control) were examined postoperatively at two and six weeks, at which time the following data were recorded: six wound measurements, total postoperative blood loss, complications of superficial infections, and reoperations.

Eligibility criteria:
inclusion criteria: * osteoathritis of knee and hip exclusion criteria: * inflammatory arthritis and hypercoagulable state

Keywords: total joint arthroplasty platelet-rich plasma activated collagen
tinnitus suppression for cochlear implant recipients

Conditions: Tinnitus

Summary: tinnitus is the perception of sound in the absence of an external sound. prevalence in the general population is 10 to 15%, with tinnitus severely impacting quality of life in 1-2 percent of the population. tinnitus therapy is based on counselling, cognitive and behavioural therapies in combination with sound therapies which mostly rely on masking. for cochlear implant candidates, the ability to use hearing aids and maskers is limited by the degree of their hearing loss. reports of tinnitus prevalence in this group range from 67 to 100% with a mean of 80%. in cochlear implant (ci) recipients, tinnitus suppression primarily occurs during active use of the cochlear implant system. in some ci recipients residual inhibition of tinnitus occurs when the implant is switched off. while the benefits of ci implantation on tinnitus are well documented, there is a group of recipients where tinnitus remains a concern in the implanted ear post-operatively. the primary aim of this study is to investigate the benefits of using tinnitus masking via a ci sound processor that optimises tinnitus suppression with minimal annoyance to the user. furthermore a questionnaire will be employed to capture the prevalence, degree and nature of tinnitus in recipients.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. freedom or ci500 series implant 3. at least 3 months experience with the cochlear implant 4. native speaker in the language used to assess speech perception performance 5. willingness to participate in and to comply with all requirements of the protocol 6. self-reported tinnitus in the implanted ear 7. reside local to investigational site exclusion criteria: 1. signs of retrocochlear or central origin to hearing impairment as confirmed by medical examination and test including mri 2. additional handicaps that would prevent participations in evaluations 3. unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the study

Keywords: cochlear implants hearing loss
prediction of duration of mechanical ventilation in acute hypoxemic respiratoty failure

Conditions: Acute Hypoxemic Respiratory Failure

Summary: acute hypoxemic respiratory failure (ahrf) is a common cause of admission in intensive care units (icus) worldwide. we will assess machine learning (ml) techniques for prediction of prolonged duration (\> or = to 7 days) of mechanical ventilation (mv) in 1,241 patients enrolled in the pandora study in spain. the study was registered with clinaltrials.gov (nct03145974). our aim is to identify a model with the minimum number of variables that predict duration of prolonged ventilation in ahrf patients using data as early as from the first 48 hours with machine learning algorithms.

acute hypoxemic respiratory failure (ahrf) is the most common cause of admission in intensive care units (icus) worldwide. the investigators will assess the value of machine learning (ml) techniques for prediction of prolonged duration (\> or equeal to 7 days) of mechanical ventilation (mv) in 1,241 patients enrolled in the pandora study in spain. few studies have investigated the prediction of prolonged mv in patients with ahrf. for model training and testing, the investigators will extract data from random pateints from the first 2 days after diagnosis of ahrf. the investigators had a database with 2,000,000 anonymized and dissociated demographics and clinically relevant data from 1,241 patients with ahrf from 22 hospitals in spain. the investigators will follow the tripod guidelines for prediction models. the investigators will screen relevant collected variables using a genetic algorithm variable selection to achieve parsimony. we will use 5-fold corss-validation in the data set of patients with data at t0, t24 and t48. we will use 25% of patients randomly selected for evaluation of the model.

Eligibility criteria:
inclusion criteria: * enotracheal intubation puls mechanical ventilation * pao2/fio2 ratio \ or =5 and fio2 \>or = 0.3 exclusion criteria: * brain death patients

Keywords: mechanical ventilation machine learning prediction of prolonged mechanical ventilation outcome
prophylactic negative wound therapy in laparotomy wounds.

Conditions: Wound Infection; Wounds; Dehisence; Cosmesis; Home Care; Length of Hospital Stay

Summary: post-operative wound issues in abdominal surgery have a significant impact on patient outcomes. the impact of different types of wound therapy are not clear in the literature. the hypothesis of this study is that npwt has the potential to reduce surgical site infections, however no study has compared the most commonly used products against standard dressings.

in the era of enhanced recovery, improving modifiable peri-operative and post-operative factors is essential to better patient outcomes. surgical site complications in the form of wound infections are a major burden to the healthcare system. negative pressure wound therapy (npwt) as delivered by a surgical incision management system (sims) is a novel approach to improve wound healing when applied to closed incisions. however, data is limited in its application to laparotomy incisions in the acute and elective care surgery setting. surgical site infections can complicate a patient's post-operative course significantly, often necessitating a longer length of stay, antibiotic therapy, intervention for wound collections and impair patient mobility and overall recovery. in addition to this, laparotomy wound complications can possibly delay adjuvant therapy and also increases healthcare costs both as an inpatient and in the community. despite significant measures to reduce such complications in the form of wound care bundles, changing of gloves prior to wound closure etc, surgical site complications continue to represent a huge healthcare burden. aim; 1. to determine if prophylactic negative pressure wound therapy confers a lower rate of superficial site infection or reduces wound complications in emergency or elective laparotomy wounds thereby improving post-operative patient recovery and reducing healthcare costs.

Eligibility criteria:
inclusion criteria: * all patients over the age of 18 years of age undergoing a laparotomy are eligible for entry into this study. benign and malignant conditions are eligible for inclusion. exclusion criteria: * pregnant patients and those undergoing re-look laparotomies are to be excluded.
investigation of the relationship between internet gaming disorder and sensorimotor functions in adolescents

Conditions: Internet Gaming Disorder

Summary: using computer for long have been shown to cause vision problems, musculoskeletal pain particularly in neck, postural deviations, obesity and physical inactivity in several studies. the relation between obesity and physical activity, neck pain and postural deviations with altered sensorimotor function has been also shown with many studies. however, there were not enough study that assess sensorimotor congruence such as proprioception and reaction time in adolescents diagnosed with internet gaming disorder (igd). this study aimed to evaluate the proprioception and reaction time and investigate its relation with the relationship with neck pain, proprioception and reaction time in adolescents with igd.

the aim of this study is to evaluate reaction time, motor dexterity, cervical posture and proprioception and its relationship with internet gaming disorder (igd) in adolescents. it's anticipated that 60 adolescents aged between 10-18 years will be included to this study (30 healthy adolescent; 30 adolescent with igd. after recording sociodemografic data of participants, age of starting to use the internet, the age of starting to play games on the internet, the time spent on the internet, the name and type of the game played will be questioned. the presence of musculoskeletal pain and its localization, if any, will be recorded. the severity of internet addiction will be assessed with internet addiction scale, motor dexterity will be assessed with the 9 hole peg test, reaction time of upper extremity will be assessed with ruler drop method, the severity of forward head posture will be assessed with cervical range of motion (crom) device, and lastly, proprioception of cervical region will be assessed with joint position error which will be evaluated crom device. all parameters will be compared between healthy adolescents and adolescents with igd.

Eligibility criteria:
inclusion criteria: for healthy group as follows: * being male in age between 10-18 years old * having accepted the research on a voluntary basis and signed the informed consent. for the experimental group, being diagnosed with igd according to dsm-5 is an additional criterion. exclusion criteria: * being diagnosed with psychotic, bipolar, or autism spectrum disorder * the presence of mental retardation in the child or family that prevents answering the questions and following the instructions properly in clinical assessment * use of psychotropic drugs.

Keywords: internet gaming disorder fine motor skills adolescent sensorimotor function
further delineation of the de santo shinawi syndrome phenotype using a series of individuals carrying a pathogenic variant of the wac gene

Conditions: WAC; DeSanto-Shinawi Syndrome; DESSH; WAC SYNDROME; OMIM#616708; ORPHA:466943

Summary: the aim of this retrospective, multicenter study would be to extend the phenotypic spectrum of desanto shinawi syndrome and improve the knowledge of its evolution. to this end, the investigators would like to issue a call for international collaboration in order to create a series of new genetically diagnosed patients, not yet described in previous publications, and with a larger number of individuals evaluated in a single study. one of the aims would be to establish a set of standardized clinical and paraclinical examinations to be carried out at diagnosis and for follow-up of affected patients. this would enable patients, their families and the caregivers involved to better anticipate future management.

main objective : update clinical and paraclinical knowledge of desanto-shinawi syndrome. secondary objectives: * inventory the clinical signs of the syndrome described to date and look for recurrence between patients. * select a set of standardized clinical and paraclinical examinations for diagnosis. * establish appropriate management and follow-up. * to compare the phenotype of patients with dessh due to a pathogenic point variation in the wac gene and those with a microdeletion involving the wac gene. main inclusion criteria: children and adults of any age. molecular diagnosis of a pathogenic variant involving the wac gene (snv, cnv, sv). main non-inclusion criteria: patients with a molecular diagnosis of another vp (snv) of a gene responsible for a neurodevelopmental disorder. patient having already participated in a dessh study with published data. no patient data available. primary endpoint: the data collected will enable the investigators to meet the objective, namely to expand clinical and paraclinical knowledge of desanto-shinawi syndrome. main secondary endpoints: na (descriptive study) statistics: na (descriptive study)

Eligibility criteria:
inclusion criteria: * children and adults of any age. * molecular diagnosis of a pathogenic (or likely pathogenic) variant involving the wac gene (snv, cnv, sv). exclusion criteria: * patients with a molecular diagnosis of another vp (snv) of a gene responsible for a neurodevelopmental disorder. * patient having already participated in a dessh study with published data. * no patient data available.

Keywords: further delineation of the de santo shinawi syndrome serie of patients with dessh better characterization of desanto-shinawi syndrome series of individuals with pathogenic wac variant wac desanto desanto-shinawi de santo shinawi dessh omim 616708 omim#616708 orpha:466943 orpha 466943
comparing eswt doses for post-stroke ankle spasticity treatment

Conditions: Stroke

Summary: post-stroke spasticity is a common complication affecting the neurological recovery, self-care daily activities and patients' quality of life. extracorporeal shock waves (eswt) have been proven therapeutic effects on decreasing spasticity and regaining function. stroke patients often suffer ankle plantar flexor spasticity with poor ankle movement control, leading to abnormal gait patterns and risk of falling; local pain appears as well in the ankle. research showed application of eswt to lower extremity spasticity reduced ankle plantar flexor spasticity, ankle pain and increased the range of ankle motion. however, the current study did not investigate the effect of eswt on different muscles in patients with post-stroke ankle spasticity. therefore, this study will compare the effect of focused eswt on combination of the gastrocnemius and soleus muscles to gastrocnemius muscle alone in the post-stroke ankle plantar flexor spasticity.

this study design was a single-blind randomized controlled trial and planned to recruit 40 chronic stroke patients with ankle plantar flexor spasticity. the patients were randomly assigned to two groups. the experimental group received focused eswt to gastrocnemius and soleus muscles (a total of 4000 shots per session), while the control group received focused eswt to gastrocnemius muscle (2000 shots per session). patients in both groups underwent a total of 4 sessions eswt, twice a week for two consecutive weeks. the primary outcome was modified ashworth scale; the secondary outcomes were modified tardieu scale, passive range of ankle motions and timed up and go test, and strain elastography. the outcomes were assessed before eswt and after eswt at 1, 4, 12, and 24 week.

Eligibility criteria:
inclusion criteria: 1. subject with cerebral stroke and age more 20 2. the degree of spasticity of plantar flexor is more than 1.( grading with the modified ashworth scale) 3. stable vital sign exclusion criteria: 1. recurrent cerebral stroke, traumatic brain injury, brain tumor or other brain related disease. 2. other central nervous system diseases (sci, parkinson's disease), or other musculoskeletal disorders which affect the result of evaluating muscle spasticity. 3. malignant tumor, coagulation disorder, infection or use of pace which were not suitable for extracorporeal shock wave. 4. received extracorporeal shock wave or botulinum injection for plantar flexor spasticity in recent 3 months. 5. subjects who was unable to complete extracorporeal shock wave or evaluation due to impaired cognition or aphasia.

Keywords: stroke spasticity shock wave ankle
study to assess the safety, tolerability, and pharmacokinetics of amp-110 in subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time in human study of amp-110 in adult subjects with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * must be able to provide written informed consent * body mass index 18.5 to 35.0 kg/m2 * diagnosis of rheumatoid arthritis according to 1987 revised american college of rheumatology (acr) criteria * global functional class i, ii, or iii according to acr 1991 revised criteria * stable use of \>/= 1 disease modifying anti-rheumatic drugs (dmard) for \>/= 4 weeks prior to day 0, including: 1. methotrexate (mtx) 7.5 - 25 mg/week 2. hydroxychloroquine (hcq) \</= 400 mg/day 3. sulfasalazine (ssz) 1,000 - 3,000 mg/day 4. leflunomide 5 - 20 mg/day 5. azathioprine 150 mg/day or 2 mg/kg/day 6. combinations of mtx, hcq, and/or ssz allowed exclusion criteria: * prior to day 0, use of 1. abatacept 2. rituximab within 6 months 3. infliximab, adalimumab, certolizumab, tocilizumab, cyclosporine, or mycophenolate mofetil within 2 months 4. etanercept or anakinra within 28 days 5. immunoglobulin or blood products within 28 days * evidence of any active or recent infection including ongoing, chronic infectious disease such as chronic renal infection or chronic chest infection with bronchiectasis or sinusitis * history of systemic autoimmune disease other than rheumatoid arthritis * history of allergic reactions to other protein therapeutics such as monoclonal antibodies or fusion proteins * history of anaphylaxis or allergic diathesis * clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram * evidence of active or latent tuberculosis * vaccination wtih live attenuated viruses within the 2 weeks prior to day 0 * evidence of infection with hepatitis b virus, hepatitis c virus, human immunodeficiency virus 1 or 2, or active infection with hepatitis a * pregnant or breastfeeding women

Keywords: arthritis rheumatoid arthritis joint diseases musculoskeletal diseases rheumatic diseases connective tissue diseases autoimmune diseases immune system diseases antirheumatic agents
a trial of ribavirin in patients with aclf due to hepatitis e virus

Conditions: Acute on Chronic Hepatic Failure; Liver Failure; Hepatitis E Infection

Summary: the term acute on chronic liver failure (aclf) describes a clinical entity characterized by an acute and rapid deterioration of liver function in a patient with previously well-compensated liver disease owing to the effects of a precipitating event. in this condition two insults act simultaneously, one being the preexisting liver injury (chronic liver disease) and the other acute injury which is responsible for the acute decompensation. hev being a major factor responsible for this clinical entity and has a very high mortality rate. ribavirin being a safe drug and has been shown to inhibit the replication of hev, can be an important drug in the treatment of these patients. therefore the present study is designed to study the impact of ribavirin in reducing the mortality due to hev related aclf.


Eligibility criteria:
inclusion criteria: * all aclf due to hev * consent to participate in trial and collection of blood. exclusion criteria: * pregnant and nursing mothers. * severe anemia * other etiologies of aclf (eg. alcohol, drugs, reactivation of hepatitis b and hepatitis c, variceal bleeding, surgical intervention and sepsis) * hepatocellular carcinoma (hcc) * hepatorenal syndrome (hrs) at admission * presence of life threatening cardiovascular, respiratory and neurological disease * acquired immunodeficiency syndrome * patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) * refusal to provide consent to participate in the study

Keywords: aclf hev ribavirin
a study to compare genetic variations of igf-i and igf-ii

Conditions: Dementia

Summary: the purpose of this study is to determine if insulin-like growth factors (igf) play a role in the development of dementia, specifically alzheimer's disease (ad). the study will compare results from genetic testing between patients with ad and two other groups: younger biological family members of the ad patients and individuals without ad matched by age to the ad patients.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 50 and 81 years old who have a diagnosis of dementia * men and women who are at least 18 years old and are biologically related to the study subject with dementia * control subjects must not have a diagnosis of dementia and must be matched in age to the study subjects with dementia exclusion criteria: * biological family members of the dementia patient who are either younger than 17 years of age or older than the patient with dementia * biological family members with a diagnosis of dementia * age-matched control subjects with a diagnosis of dementia

Keywords: dementia insulin-like growth factor igf apo e4 genetics